Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the safety and tolerability of six escalating
doses of SCIO-469 in RA patients. SCIO-469 belongs to a new class of treatments that inhibit
p38 kinase, a stimulatory modulator of pro-inflammatory factors including tumor necrosis
factor-alpha (TNF-alpha), interleukin-1 (IL-1), and cyclooxygenase-2 (COX-2), all of which
are known to contribute to both symptoms and disease progression in patients with Rheumatoid
Arthritis.